It is interesting that disruption of CD147 and CypA/B enhancement of SARS-CoV-2 entry has been suggested as a viable therapeutic strategy for the treatment of COVID-19 (52, 53, 54); however, the mechanism of CD147 enhancement of SARS-CoV-2 entry as well as its possible role in SARS-CoV-2 pathogenesis is currently unclear and requires investigation. This evidence concerns the gene BSG and COVID-19.